Appetite Suppressant Overrides Opioid-Driven Hunger — But Not Through Serotonin

Dexfenfluramine's appetite-suppressing effect dominated over opioid peptide feeding stimulation in rats, and the interaction did not involve brain serotonin changes.

Robert, J J et al.·Pharmacology·1991·Preliminary EvidenceAnimal StudyAnimal Study
RPEP-00208Animal StudyPreliminary Evidence1991RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Animal Study
Evidence
Preliminary Evidence
Sample
Not reported

What This Study Found

Dexfenfluramine's anorectic effect dominated over opioid agonist feeding stimulation. The interaction was not mediated by brain serotonin turnover changes.

Key Numbers

How They Did This

Rats received central injections of opioid agonists (beta-endorphin, dynorphin, DSLET) or naltrexone, alone or combined with d-FF. Food intake and brain serotonin turnover were measured.

Why This Research Matters

Understanding how appetite-stimulating (opioid) and appetite-suppressing (serotonergic) systems interact is key to developing better weight loss treatments.

The Bigger Picture

Understanding how appetite-stimulating and appetite-suppressing systems interact is key to obesity treatment. This study showed serotonergic appetite suppression can override opioid-driven hunger.

What This Study Doesn't Tell Us

Animal study in rats with central drug administration. Doses and routes do not reflect clinical use. d-FF was later withdrawn from human use due to safety concerns.

Questions This Raises

  • ?What mechanism underlies the dexfenfluramine-opioid interaction if not serotonin?
  • ?Could combination therapies targeting both systems improve weight loss?

Trust & Context

Key Stat:
Suppression dominated stimulation Dexfenfluramine's anorectic effect overrode opioid agonist feeding stimulation without altering brain serotonin turnover
Evidence Grade:
Preliminary animal study. The drug was later withdrawn from human use due to safety concerns.
Study Age:
Published in 1991. Dexfenfluramine was withdrawn in 1997 due to heart valve problems, but the principles of appetite system interactions remain relevant.
Original Title:
Effects of dexfenfluramine and opioid peptides, alone or in combination, on food intake and brain serotonin turnover in rats.
Published In:
Pharmacology, biochemistry, and behavior, 38(4), 775-80 (1991)
Database ID:
RPEP-00208

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / Observational
Case Report / Animal StudyOne case or non-human subjects
This study

Tests effects in animals (usually mice or rats), not humans.

What do these levels mean? →

Frequently Asked Questions

Why was dexfenfluramine withdrawn?

It was removed from the market in 1997 because it caused heart valve damage in some patients. However, the appetite research findings remain scientifically valid.

Does this mean serotonin drugs can overcome opioid hunger?

In this model, yes. Serotonergic appetite suppression dominated over opioid-driven feeding. Modern weight loss drugs like lorcaserin (also later withdrawn) worked on similar principles.

Read More on RethinkPeptides

Cite This Study

RPEP-00208·https://rethinkpeptides.com/research/RPEP-00208

APA

Robert, J J; Orosco, M; Rouch, C; Cohen, Y; Jacquot, C. (1991). Effects of dexfenfluramine and opioid peptides, alone or in combination, on food intake and brain serotonin turnover in rats.. Pharmacology, biochemistry, and behavior, 38(4), 775-80.

MLA

Robert, J J, et al. "Effects of dexfenfluramine and opioid peptides, alone or in combination, on food intake and brain serotonin turnover in rats.." Pharmacology, 1991.

RethinkPeptides

RethinkPeptides Research Database. "Effects of dexfenfluramine and opioid peptides, alone or in ..." RPEP-00208. Retrieved from https://rethinkpeptides.com/research/robert-1991-effects-of-dexfenfluramine-and

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.